Aptose Biosciences Inc. (APTOF)
OTCMKTS · Delayed Price · Currency is USD
1.260
-0.040 (-3.08%)
Oct 28, 2025, 9:30 AM EDT
Aptose Biosciences Employees
Aptose Biosciences had 13 employees as of December 31, 2024. The number of employees decreased by 23 or -63.89% compared to the previous year.
Employees
13
Change (1Y)
-23
Growth (1Y)
-63.89%
Revenue / Employee
n/a
Profits / Employee
-$1,624,923
Market Cap
3.19M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 13 | -23 | -63.89% |
| Dec 31, 2023 | 36 | 0 | - |
| Dec 31, 2022 | 36 | -6 | -14.29% |
| Dec 31, 2021 | 42 | 1 | 2.44% |
| Dec 31, 2020 | 41 | 8 | 24.24% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| American Oncology Network | 1,914 |
| Jushi Holdings | 1,234 |
| Glass House Brands | 374 |
| Silence Therapeutics | 116 |
| Elite Pharmaceuticals | 68 |
| Northwest Biotherapeutics | 25 |
| CytoDyn | 13 |
| Nuo Therapeutics | 9 |
Aptose Biosciences News
- 13 days ago - Aptose's Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML - GlobeNewsWire
- 2 months ago - Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor - GlobeNewsWire
- 2 months ago - Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial - GlobeNewsWire
- 2 months ago - Aptose Reports Second Quarter 2025 Results - GlobeNewsWire
- 2 months ago - Aptose Enrollment is Open for 160 mg Dosing Cohort of Tuspetinib in Phase 1/2 TUSCANY Trial of Frontline Triple Drug Therapy - GlobeNewsWire
- 3 months ago - Aptose Selects Ernst & Young Global Limited as its New Independent Auditor and Calls Reconvened Meeting of its Shareholders - GlobeNewsWire
- 3 months ago - Aptose Receives Second Advance under the Loan Agreement with Hanmi Pharmaceutical to Continue Development of Tuspetinib in Triplet Therapy for AML - GlobeNewsWire
- 4 months ago - Aptose Upgraded to Trade on OTCQB Market - GlobeNewsWire